Ved­aBio launch­es with $40M+ in ini­tial fund­ing for CRISPR-based mol­e­c­u­lar de­tec­tion tech­nol­o­gy

Cal­i­for­nia biotech Ved­aBio de­buted on Tues­day with more than $40 mil­lion in ear­ly fund­ing to sup­port its CRISPR-dri­ven mol­e­c­u­lar de­tec­tion plat­form, which it claims could tran­scend the need for tar­get am­pli­fi­ca­tion.

The fundraise was backed by lead in­vestor OMX Ven­tures with help from a hand­ful of fam­i­ly of­fices. Ved­aBio was found­ed by CEO Anu­rup Gan­guli and bio­engi­neer­ing pro­fes­sor Rashid Bashir, who worked to­geth­er at Bashir’s lab at the Uni­ver­si­ty of Illi­nois.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.